<DOC>
	<DOCNO>NCT02046603</DOCNO>
	<brief_summary>This open-label study evaluate efficacy safety RoActemra/Actemra ( tocilizumab ) monotherapy combination methotrexate non-biologic DMARDs patient active rheumatoid arthritis inadequate response current non-biologic DMARD therapy first anti-TNF agent . Patients receive RoActemra/Actemra 162 mg subcutaneously weekly 52 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Monotherapy Combination With Methotrexate Other Non-Biologic DMARDs Patients With Active Rheumatoid Arthritis Inadequate Response Current Non-Biologic DMARD Therapy First Anti-TNF Biologic Agent</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Active rheumatoid arthritis accord revise ( 1987 ) ACR criterion EULAR/ACR ( 2010 ) criterion Patients inadequate response current nonbiologic DMARD therapy first antiTNF agent ( monotherapy combination MTX nonbiologic DMARDs ) . Inadequate response antiTNF treatment define achieve adequate response treatment 24 week minimum period 12 week therapy permit local guidance , define DAS28 score improvement le 1.2 patient achieve DAS28 score improvement 1.2 acheiving low disease activity ( current DAS28ESR 3.2 ) No previous exposure RoActemra/Actemra ( tocilizumab ) Oral corticosteroid ( &lt; /= 10 mg/day prednisone equivalent ) nonsteroidal antiinflammatory drug ( NSAIDs ; recommend dose ) permit stable dose regimen &gt; /= 4 week prior baseline Permitted nonbiologic DMARDs allow stable dose least 4 week prior baseline Receiving treatment outpatient basis , include RoActemra/Actemra Females childbearing potential male female partner childbearing potential must agree use reliable mean contraception define protocol study least 3 month follow last dose RoActemra/Actemra Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow baseline Rheumatic autoimmune disease rheumatoid arthritis ( RA ) Functional Class IV define ACR Classification Functional Status Rheumatoid Arthritis Diagnosis juvenile idiopathic arthritis juvenile RA and/or RA age 16 Prior history current inflammatory joint disease RA Exposure tocilizumab either intravenous SC time prior baseline Treatment investigational agent within 4 week ( 5 halflives investigational drug , whichever long ) screen Intraarticular parenteral corticosteroid within 4 week prior baseline History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody Known active current history recurrent infection Major episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week screen Active TB require treatment within previous 3 year Positive hepatitis B hepatitis C virus infection Primary secondary immunodeficiency ( history currently active ) Pregnant lactate woman Inadequate hematologic , renal liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>